Sangamo Therapeutics Inc (NASDAQ:SGMO) Director Saira Ramasastry sold 9,450 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $24.88, for a total value of $235,116.00. Following the completion of the sale, the director now directly owns 9,450 shares of the company’s stock, valued at $235,116. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) traded down $0.40 during midday trading on Wednesday, hitting $25.60. The company had a trading volume of 1,471,758 shares, compared to its average volume of 2,101,455. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $2,244.81, a price-to-earnings ratio of -36.57 and a beta of 2.60. Sangamo Therapeutics Inc has a twelve month low of $3.85 and a twelve month high of $27.50.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The business had revenue of $13.08 million during the quarter, compared to analyst estimates of $11.10 million. During the same period in the prior year, the company posted ($0.14) earnings per share. Sangamo Therapeutics’s revenue was up 46.6% on a year-over-year basis. equities analysts anticipate that Sangamo Therapeutics Inc will post 0.04 EPS for the current year.
SGMO has been the subject of several research reports. Barclays reissued a “buy” rating and issued a $30.00 price objective on shares of Sangamo Therapeutics in a research report on Sunday, February 25th. Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Finally, Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, November 15th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $20.83.
Institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC boosted its holdings in Sangamo Therapeutics by 10.7% in the second quarter. Voya Investment Management LLC now owns 33,809 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 3,270 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Sangamo Therapeutics by 29.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 4,300 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in Sangamo Therapeutics by 13.5% during the third quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock worth $673,000 after buying an additional 5,337 shares during the last quarter. Swiss National Bank boosted its holdings in Sangamo Therapeutics by 3.9% during the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock worth $2,336,000 after buying an additional 5,400 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Sangamo Therapeutics by 7.4% during the third quarter. Rhumbline Advisers now owns 88,816 shares of the biopharmaceutical company’s stock worth $1,332,000 after purchasing an additional 6,125 shares during the period. Hedge funds and other institutional investors own 65.74% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.